Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis

Author(s): Rohina Bashir, Mir Mahmood Asrar, Idrees Ayoub Shah, Imtiyaz Ahmad Wani and Mohd. Ashraf Ganie*

Volume 29, Issue 19, 2023

Published on: 27 June, 2023

Page: [1486 - 1496] Pages: 11

DOI: 10.2174/1381612829666230331093912

Price: $65

conference banner
Abstract

Background: Spironolactone use as a treatment for hirsutism and other dermatological conditions among polycystic ovary syndrome (PCOS) and idiopathic hirsutism shows varied results.

Objective: This study thus summarizes the entire evidence to better define its impact on Ferriman-Gallwey (FG) score in addition to other derangements associated with PCOS.

Methods: PubMed, Embase, Scopus and bibliographies of relevant articles were searched. Randomized controlled trails (RCTs) investigating the efficacy of spironolactone in PCOS and idiopathic hirsutism were included. Pooled mean difference (MD) was calculated using random effects model and relevant subgroup analysis was done. Potential heterogeneity and publication bias was assessed.

Results: Of 1041 retrieved studies, 24 RCTs were included. Spironolactone (100 mg/daily) exhibited a significant reduction in FG score in idiopathic hirsutism compared to finasteride (MD: -2.43; 95% C.I: -3.29, -1.57) and cyproterone acetate (MD: -1.18; 95% C.I: -2.10, -0.26), however, no significant difference was found among PCOS subjects in comparison to flutamide and finasteride. A lower dose of spironolactone (50 mg/day) exhibited no significant difference relative to metformin on FG Score (MD: -0.61; 95% C.I: -1.76, 0.54, I2 = 57%), serum total testosterone (MD: -0.61; 95% C.I: -1.76, 0.54), I2 = 57% and HOMA-IR (MD: 1.03; 95% C.I: -1.22, 3.29), I2 = 60% among PCOS women. The main side effects reported by the studies were menstrual irregularity, mild nausea, vomiting and diarrhea.

Conclusion: Spironolactone is well tolerated among idiopathic hirsute and PCOS women. The drug significantly improved hirsutism in the former group and shows a positive trend in the latter women, however, displays no effect on FSH, LH, menstrual cyclicity, BMI, and HOMA-IR in PCOS women.

« Previous Next »
[1]
Shuey M, Perkins B, Nian H, Yu C, Luther JM, Brown N. Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. BMJ open 2020; 10(5): e033100.
[http://dx.doi.org/10.1136/bmjopen-2019-033100]
[2]
Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55 (Suppl. 6): 1-12.
[http://dx.doi.org/10.1136/gut.2006.099580] [PMID: 16966752]
[3]
Patibandla S, Heaton J, Kyaw H. Spironolactone. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023.
[PMID: 32119308]
[4]
Stripp B, Taylor AA, Bartter FC, et al. Effect of spironolactone on sex hormones in man. J Clin Endocrinol Metab 1975; 41(4): 777-81.
[http://dx.doi.org/10.1210/jcem-41-4-777] [PMID: 1176584]
[5]
Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 1975; 97(1): 52-8.
[http://dx.doi.org/10.1210/endo-97-1-52] [PMID: 166833]
[6]
Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94(9): 3132-54.
[http://dx.doi.org/10.1210/jc.2009-0345] [PMID: 19509099]
[7]
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol 2017; 18(2): 169-91.
[http://dx.doi.org/10.1007/s40257-016-0245-x] [PMID: 28155090]
[8]
Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol 2000; 52(5): 587-94.
[http://dx.doi.org/10.1046/j.1365-2265.2000.00982.x] [PMID: 10792338]
[9]
Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Libr 2009; (2): CD000194.
[http://dx.doi.org/10.1002/14651858.CD000194.pub2] [PMID: 19370553]
[10]
Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris: Practical considerations for the clinician based on current data and clinical experience. J Clin Aesthet Dermatol 2012; 5(3): 37-50.
[PMID: 22468178]
[11]
Kanbour SA, Dobs AS. Hyperandrogenism in women with polycystic ovarian syndrome: pathophysiology and controversies. Androgens. Clinical Research and Therapeutics 2022; 3(1): 22-30.
[http://dx.doi.org/10.1089/andro.2021.0020]
[12]
Rao M, Broughton KS, LeMieux MJ. Cross-sectional study on the knowledge and prevalence of PCOS at a Multiethnic University. Prog Prev Med 2020; 5(2): e0028.
[http://dx.doi.org/10.1097/pp9.0000000000000028]
[13]
Teede H, Gibson-Helm M, Norman RJ, Boyle J. Polycystic ovary syndrome: Perceptions and attitudes of women and primary health care physicians on features of PCOS and renaming the syndrome. J Clin Endocrinol Metab 2014; 99(1): E107-11.
[http://dx.doi.org/10.1210/jc.2013-2978] [PMID: 24178791]
[14]
Hayes MG, Urbanek M, Ehrmann DA, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015; 6(1): 7502.
[http://dx.doi.org/10.1038/ncomms8502] [PMID: 26284813]
[15]
Crete J, Adamshick P. Managing polycystic ovary syndrome: what our patients are telling us. J Holist Nurs 2011; 29(4): 256-66.
[http://dx.doi.org/10.1177/0898010111398660] [PMID: 21357181]
[16]
Fatemeh B, Shahideh JS, Negin M. Health related quality of life and psychological parameters in different polycystic ovary syndrome phenotypes: A comparative cross-sectional study. J Ovarian Res 2021; 14(1): 21-811.
[17]
Almalki HH, Alshibani TM, Alhifany AA, Almohammed OA. Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: A network meta-analysis of randomized clinical trials. BMC Womens Health 2020; 20(1): 68.
[http://dx.doi.org/10.1186/s12905-020-00919-5] [PMID: 32248801]
[18]
Bulsara JP, Patel P, Soni A, Acharya S. A review: Brief insight into polycystic ovarian syndrome. Endocrinol Metab 2021; 3: 100085.
[http://dx.doi.org/10.1016/j.endmts.2021.100085]
[19]
Carlos-Escalante JA, de Jesús-Sánchez M, Rivas-Castro A, Pichardo-Rojas PS, Arce C, Wegman-Ostrosky T. The use of antihypertensive drugs as coadjuvant therapy in cancer. Front Oncol 2021; 11: 660943.
[http://dx.doi.org/10.3389/fonc.2021.660943] [PMID: 34094953]
[20]
Zhang Z, Zhou L, Xie N, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther 2020; 5(1): 113.
[http://dx.doi.org/10.1038/s41392-020-00213-8] [PMID: 32616710]
[21]
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372(71): n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[22]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-60.
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[23]
Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: An open-labeled study. J Clin Endocrinol Metab 2004; 89(6): 2756-62.
[http://dx.doi.org/10.1210/jc.2003-031780] [PMID: 15181054]
[24]
Ganie MA, Khurana ML, Nisar S, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): A six-month, open-label randomized study. J Clin Endocrinol Metab 2013; 98(9): 3599-607.
[http://dx.doi.org/10.1210/jc.2013-1040] [PMID: 23846820]
[25]
Ganie MA, Rashid A, Sood M, et al. Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. Gynecol Endocrinol 2020; 36(4): 308-12.
[http://dx.doi.org/10.1080/09513590.2019.1675044] [PMID: 31701799]
[26]
Alpañés M, Álvarez-Blasco F, Fernández-Durán E, Luque-Ramírez M, Escobar-Morreale HF. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: A one-year randomized clinical trial. Eur J Endocrinol 2017; 177(5): 399-408.
[http://dx.doi.org/10.1530/EJE-17-0516] [PMID: 28912358]
[27]
Leelaphiwat S, Jongwutiwes T, Lertvikool S, et al. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial. J Obstet Gynaecol Res 2015; 41(3): 402-10.
[http://dx.doi.org/10.1111/jog.12543] [PMID: 25319761]
[28]
Diri H, Karaburgu S, Acmaz B, et al. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. Gynecol Endocrinol 2016; 32(1): 42-5.
[http://dx.doi.org/10.3109/09513590.2015.1080679] [PMID: 26370923]
[29]
Mazza A, Fruci B, Guzzi P, et al. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis 2014; 24(2): 132-9.
[http://dx.doi.org/10.1016/j.numecd.2013.04.016] [PMID: 23845740]
[30]
Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30(3): 471-8.
[http://dx.doi.org/10.2337/dc06-0618] [PMID: 17327307]
[31]
Keleştimur F, Everest H, Unlühizarci K, Bayram F, Sahin Y. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 2004; 150(3): 351-4.
[http://dx.doi.org/10.1530/eje.0.1500351] [PMID: 15012621]
[32]
Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet 2010; 281(1): 35-42.
[http://dx.doi.org/10.1007/s00404-009-1051-y] [PMID: 19330342]
[33]
Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril 2003; 79(4): 942-6.
[http://dx.doi.org/10.1016/S0015-0282(02)04927-0] [PMID: 12749435]
[34]
Erenus M, Yücelten D, Durmuşoǧlu F, Gürbüz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril 1997; 68(6): 1000-3.
[http://dx.doi.org/10.1016/S0015-0282(97)00371-3] [PMID: 9418687]
[35]
Erenus M, Gürbüz O, Durmuşoğlu F, Demirçay Z, Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil Steril 1994; 61(4): 613-6.
[http://dx.doi.org/10.1016/S0015-0282(16)56634-5] [PMID: 8150100]
[36]
Inal MM, Yildirim Y, Taner CE. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: A randomized controlled study. Fertil Steril 2005; 84(6): 1693-7.
[http://dx.doi.org/10.1016/j.fertnstert.2005.05.051] [PMID: 16359967]
[37]
Ünlühızarcı K, Everest H, Bayram F, Keleştimur F. Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Fertil Steril 2002; 78(6): 1331-3.
[http://dx.doi.org/10.1016/S0015-0282(02)04294-2] [PMID: 12477537]
[38]
Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85(1): 89-94.
[http://dx.doi.org/10.1210/jc.85.1.89] [PMID: 10634370]
[39]
Gökmen O, Şenöz S, Gülekli B, Işlk AZ. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome Gynecol Endocrinol 1996; 10(4): 249-55.
[http://dx.doi.org/10.3109/09513599609012316] [PMID: 8908525]
[40]
Erenus M, Yücelten D, Gürbüz O. Durmuşoğlu F, Pekin S. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril 1996; 66(2): 216-9.
[http://dx.doi.org/10.1016/S0015-0282(16)58441-6] [PMID: 8690104]
[41]
Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995; 80(1): 233-8.
[PMID: 7829618]
[42]
O’Brien RC, Cooper ME, Murray RML, Seeman E, Thomas AK, Jerums G. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. J Clin Endocrinol Metab 1991; 72(5): 1008-13.
[http://dx.doi.org/10.1210/jcem-72-5-1008] [PMID: 1827125]
[43]
McLellan AR, Rentoul J, MacKie R, McInnes GT. Lack of effect of spironolactone on hair shaft diameter in hirsute females. Postgrad Med J 1989; 65(765): 459-62.
[http://dx.doi.org/10.1136/pgmj.65.765.459] [PMID: 2690044]
[44]
Sert M, Tetiker T, Kirim S. Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. Acta Med Okayama 2003; 57(2): 73-6.
[PMID: 12866746]
[45]
Kelekci KH, Kelekci S, Yengel I, Gul S, Yilmaz B. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens. J Dermatolog Treat 2012; 23(3): 177-83.
[http://dx.doi.org/10.3109/09546634.2010.519766] [PMID: 21254871]
[46]
Karakurt F, Sahin I, Güler S, et al. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomised controlled study. Adv Ther 2008; 25(4): 321-8.
[http://dx.doi.org/10.1007/s12325-008-0039-5] [PMID: 18389188]
[47]
Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009; 15(4): 477-88.
[http://dx.doi.org/10.1093/humupd/dmp008] [PMID: 19279045]
[48]
Hussein RN, Al Hamdi KI, Mansour AA. Association between biochemical hyperandrogenism parameters and modified Ferriman-Gallwey score in patients with hirsutism in Basrah (Southern Iraq). Postepy Dermatol Alergol 2021; 38(4): 603-7.
[49]
Mahajan VK, Singh Chauhan P, Chandel M, et al. Clinico-investigative attributes of 122 patients with hirsutism: A 5-year retrospective study from India. Int J Womens Dermatol 2021; 7(3): 237-42.
[http://dx.doi.org/10.1016/j.ijwd.2020.11.007] [PMID: 34222577]
[50]
Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018; 103(4): 1233-57.
[http://dx.doi.org/10.1210/jc.2018-00241] [PMID: 29522147]
[51]
Rozner RN, Freites-Martinez A, Shapiro J, Geer EB, Goldfarb S, Lacouture ME. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat 2019; 174(1): 15-26.
[http://dx.doi.org/10.1007/s10549-018-4996-3] [PMID: 30467659]
[52]
Spritzer PM, Ramos RB, Marchesan LB, de Oliveira M, Carmina E. Metabolic profile of women with PCOS in Brazil: A systematic review and meta-analysis. Diabetol Metab Syndr 2021; 13(1): 18.
[http://dx.doi.org/10.1186/s13098-021-00636-5] [PMID: 33593439]
[53]
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2017; 11(11): CD003053.
[54]
Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clin Sci 2012; 122(6): 253-70.
[http://dx.doi.org/10.1042/CS20110386] [PMID: 22117616]
[55]
Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005; 28(3): 49-53.
[http://dx.doi.org/10.1007/BF03345529] [PMID: 15816371]
[56]
Bajuk Studen K, Šebeštjen M, Pfeifer M, Preželj J. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2011; 164(3): 389-95.
[http://dx.doi.org/10.1530/EJE-10-0709] [PMID: 21156647]
[57]
Zhao JV, Xu L, Lin SL, Schooling CM. Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials. J Am Soc Hypertens 2016; 10(8): 671-82.
[http://dx.doi.org/10.1016/j.jash.2016.05.013] [PMID: 27372428]
[58]
Long T, Zhang Y, Zeng C, Zheng S, Zhou L, Liu H. Effects of low-dose spironolactone combined with metformin or either drug alone on insulin resistance in patients with polycystic ovary syndrome: A pilot study. Int J Endocrinol 2022; 2022: 9927240.
[http://dx.doi.org/10.1155/2022/9927240]
[59]
Tsujimoto T, Kajio H. Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension. J Am Heart Assoc 2020; 9(23): e018827.
[http://dx.doi.org/10.1161/JAHA.120.018827] [PMID: 33222584]
[60]
Brown MJ, Williams B, Morant SV, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): A parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2016; 4(2): 136-47.
[http://dx.doi.org/10.1016/S2213-8587(15)00377-0] [PMID: 26489809]
[61]
Christy NA, Franks AS, Cross LB. Spironolactone for hirsutism in polycystic ovary syndrome. Ann Pharmacother 2005; 39(9): 1517-21.
[http://dx.doi.org/10.1345/aph.1G025] [PMID: 16076921]
[62]
Armanini D, Andrisani A, Bordin L, Sabbadin C. Spironolactone in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother 2016; 17(13): 1713-5.
[http://dx.doi.org/10.1080/14656566.2016.1215430] [PMID: 27450358]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy